Acyclic Acid Or Salt Thereof Patents (Class 514/578)
-
Patent number: 6232346Abstract: This invention provides a dietary supplement comprising L-Carnitine (or its functional analogues such as Acetyl-Carnitine or Proprionyl-1-Carnitine), Coenzyme Q10 and Taurine for the correction of the abnormality in mitochondrial energetics in cardiac failure and certain other diseases. A high protein nutritional feeding supplementation with Cysteine, Creatine, Vitamin E (RRR-d-alpha-tocopherol), Vitamin C (ascorbic acid), Selenium, and Thiamin in may be added.Type: GrantFiled: October 7, 1999Date of Patent: May 15, 2001Inventors: Michael J. Sole, Khursheed N. Jeejeebhoy
-
Patent number: 6225295Abstract: A method of treating patients suffering from acetaminophen overdose is disclosed. The method comprises administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.Type: GrantFiled: September 27, 2000Date of Patent: May 1, 2001Inventors: Frederick H. Hausheer, Seetharamulu Peddaiahgari
-
Patent number: 6221838Abstract: This invention describes methods of treating conditions associated with an excess of neuropeptide Y which comprises administering an analog of an obesity protein. This invention further describes methods of treating conditions associated with an excess of neuropeptide Y which coomprises administering an analog of an obesity protein in combination with a neuropeptide Y antagonist. This invention demonstrates that the obesity protein acts by reducing the production of neuropeptide Y by the hypothalamus.Type: GrantFiled: June 28, 1996Date of Patent: April 24, 2001Assignee: Eli Lilly and CompanyInventors: Juliana Maude Bue-Valleskey, Mark Louis Heiman, Thomas Wesley Stephens, Frank C. Tinsley
-
Patent number: 6218435Abstract: A method of reducing hair growth in a mammal includes applying, to an area of skin from which reduced hair growth is desired, a dermatologically acceptable composition containing a suppressor of the metabolic pathway for the conversion of glucose to acetyl-CoA.Type: GrantFiled: July 17, 1998Date of Patent: April 17, 2001Inventors: James Henry, Gurpreet Ahluwalia, Douglas Shander
-
Patent number: 6177411Abstract: This invention relates to a method of treating patients afflicted with heavy metal poisoning. The method includes administering to a patient in need of treatment an antidotal amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.Type: GrantFiled: February 9, 1999Date of Patent: January 23, 2001Assignee: BioNumerik Pharmaceuticals, Inc.Inventor: Frederick Herman Hausheer
-
Patent number: 6169110Abstract: Methods of accelerating skin rejuvenation and methods of skin care treatment are disclosed using a combination of vitamin A and alphahydroxy acids, such as the combination of vitamin A propionate and glycolic acid. The combination can be prepared in an alcohol-based carrier having concentrations ranging from approximately 0.01% to 10% vitamin A propionate, preferably 0.1% to 4%, and 0.1% to 30% glycolic acid, preferably 2% to 10% glycolic acid. In addition to alcohol, the carrier may also include propylene glycol, preservatives, thickeners and non-ionic surfactants or may be a cream or ointment-based formulation. The formulation is applied topically to the skin at a frequency which will produce a fine desquamation. The formulation may also be used to accelerate the penetration of other therapeutic agents into the skin.Type: GrantFiled: May 22, 1997Date of Patent: January 2, 2001Assignee: Vivant PharmaceuticalsInventor: James E. Fulton, Jr.
-
Patent number: 6136862Abstract: A cerebral function improving agent containing as the active ingredient a compound represented by the following formula: ##STR1## wherein R.sub.2 represents a hydrogen atom when R.sub.1 is a hydroxyl group;or R.sub.1 or R.sub.1 are combined together to form an oxo group;R.sub.3 represents a hydrogen atom, an alkali metal, or a monohydric, dihydric or trihydric alcohol residue,which may be an oligomer composed of 2-10 molecules when R.sub.1 represents a hydroxyl group and R.sub.2 and R.sub.3 represent hydrogen atoms.The agent suppresses cerebral edema, protects cerebral function, impaired cerebral energy metabolism, and reduces the extent of cerebral infarction.Type: GrantFiled: November 26, 1996Date of Patent: October 24, 2000Assignee: Shimizu Pharmaceutical Co., Ltd.Inventors: Atsushi Hiraide, Sekiko Dohi, Motohisa Suzuki, Yoshihiro Shiba
-
Patent number: 6124314Abstract: This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.Type: GrantFiled: September 28, 1998Date of Patent: September 26, 2000Assignee: Pfizer Inc.Inventors: Kimberly O. Cameron, Bruce A. Lefker, Robert L. Rosati
-
Patent number: 6077828Abstract: The present invention relates to methods and nutritional compositions for the prevention and treatment of cachexia and anorexia. The methods of the invention comprise administering a composition comprising effective amounts of .omega.-3 fatty acids such as alpha-linolenic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid or mixtures thereof; of branched-chain amino acids valine, leucine, isoleucine or mixtures thereof; with or without reduced levels of tryptophan and 5-hydroxytryptophan; and of antioxidant system selected from the group comprising beta-carotene, vitamin C, vitamin E, selenium, or mixtures thereof.Type: GrantFiled: April 24, 1997Date of Patent: June 20, 2000Assignee: Abbott LaboratoriesInventors: Bonnie Chandler Abbruzzese, Mark Anthony McCamish, Frederick Oliver Cope, Stephen Joseph Demichele
-
Patent number: 6075053Abstract: This invention relates to a method of treating patients afflicted with peripheral neuropathy. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.Type: GrantFiled: February 9, 1999Date of Patent: June 13, 2000Assignee: BioNumerik Pharmaceuticals, Inc.Inventor: Frederick Herman Hausheer
-
Patent number: 6054139Abstract: The invention relates to a cleaning and/or disinfecting composition comprising a tertiary alkyl amine and an alkyl betaine.Type: GrantFiled: May 9, 1997Date of Patent: April 25, 2000Assignee: Diversey Lever Inc.Inventors: Ronald Joseph Lambert, Moira Diane Johnston, Eduard C. van Baggem, Gijsbertus de Goederen
-
Patent number: 6043274Abstract: This invention relates to a method of treating patients afflicted with diabetic cardiomyopathy. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.Type: GrantFiled: October 21, 1999Date of Patent: March 28, 2000Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Aulma Parker, Seetharamulu Peddaiahgari
-
Patent number: 6034126Abstract: This invention relates to a method of treating patients afflicted with glycol poisoning. The method includes administering to a patient in need of treatment an antidotal amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.Type: GrantFiled: May 24, 1999Date of Patent: March 7, 2000Assignee: BioNumerik Pharmaceuticals, Inc.Inventor: Frederick Herman Hausheer
-
Patent number: 6015835Abstract: The invention relates to methods for inducing analgesia (or even anesthesia) and for prevention or amelioration of damage caused by ischemic or traumatic injury of tissues in general, but especially neural, for the central nervous system being the most vulnerable of all tissues, by the systemic administration of a therapeutically effective amount of primarily taurine, and secondarily homotaurine and/or methionine for a sufficient period of time (several hours to a few days, depending on the severity of the injury, and timing when therapy is initiated from the time of injury) to allow recovery from the original insult or from phenomena that follow the initial injury.Type: GrantFiled: February 24, 1998Date of Patent: January 18, 2000Assignee: Meddiss, IncorporatedInventors: Tadaomi Miyamoto, Koho Miyamoto
-
Patent number: 6004958Abstract: The present invention is based on the discovery of a metabolic pathway in which a specific kinase converts fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction. Fructose-lysine-3-phosphate (FL3P) is then broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins), which are believed to be a cause of diabetic complications. Disclosed is a class of compounds which inhibit the action of FL3P kinase in the above-mentioned pathway.Type: GrantFiled: February 5, 1997Date of Patent: December 21, 1999Assignee: Fox Chase Cancer CenterInventors: Truman R. Brown, Francis Kappler, Benjamin Szwergold, Sundeep Lal, Bangying Su
-
Patent number: 5998479Abstract: This invention relates to a method of treating patients afflicted with Adult Respiratory Distress Syndrome (ARDS). The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.Type: GrantFiled: February 9, 1999Date of Patent: December 7, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventor: Frederick Herman Hausheer
-
Patent number: 5948443Abstract: The present invention pertains generally to the field of Public Health, including the prevention and treatment of coronary heart disease which is currently the first cause of death in the American population. More specifically, the present invention concerns a total modular system of multivitamin and mineral supplementation composed of 7 distinct modules for improving public health by insuring adequate intake of micronutrients needed for disease prevention and protection against nutritional losses and deficiencies due to, for example, lifestyle factors and common inadequate dietary patterns. A module, as used herein throughout, is defined as a separate and distinct combination of vitamin-mineral and other health promoting compounds which are directed to specific target populations. The formulations of the present invention which, when combined in one capsule or tablet or as separate modules, exert a joint and enhancing effect on the major pathogenetic factors involved in the atherosclerotic process.Type: GrantFiled: February 21, 1997Date of Patent: September 7, 1999Assignee: Medical Doctor's Research Institute, Inc.Inventors: Patricia A. Riley, George Christakis
-
Patent number: 5939456Abstract: The invention relates to novel compositions and to methods for the pulsed administration of compositions to a patient or to cells in vitro for the treatment of human blood disorders. Compositions contain chemical compounds that stimulate the expression of fetal hemoglobin and/or stimulate the proliferation of red blood cells, white blood cells and platelets in patients and ex vivo for reconstitution of hematopoiesis in vivo. These methods are useful to treat or prevent the symptoms associated with anemia, sickle cell disease, thalassemia and other blood disorders. The invention also relates to methods for the pulsed administration of compositions to patients for the treatment and prevention of cell proliferative disorders including deficiencies such as cytopenia and malignancies such as viral-induced tumors, other forms of neoplasia and for expansion of cells for hematopoietic transplantation. Pulsed administration has been shown to be more effective than continuous therapy in patients tested.Type: GrantFiled: July 26, 1996Date of Patent: August 17, 1999Inventor: Susan P. Perrine
-
Patent number: 5939458Abstract: Mammalian hair growth is reduced by applying an inhibitor of aminoacyl-tRNA synthetase to the skin.Type: GrantFiled: September 22, 1997Date of Patent: August 17, 1999Inventors: James P. Henry, Gurpreet S. Ahluwalia
-
Patent number: 5932229Abstract: Described are the use of compounds of Formula (I), depicted below, as active principals for treating skin conditions; compositions containing these compounds; and methods of treating skin conditions using these compounds and compositions. ##STR1## wherein R.sub.4 is (CR.sub.5 R.sub.6 --CR.sub.7 R.sub.8 --X.sub.1).sub.n --CR.sub.9 R.sub.10 --C(.dbd.X.sub.2)X.sub.3 R.sub.11, n is an integer from 1 to 18; R.sub.1, R.sub.2, R.sub.3, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11, are independently, hydrogen or non-hydrogen substituents; and X, X.sub.1, X.sub.2, X.sub.3, Y and Z are independently, O, NH, or S.Type: GrantFiled: May 2, 1997Date of Patent: August 3, 1999Assignee: Avon Products, Inc.Inventors: Dmitri Ptchelintsev, Neil Scancarella, Robert Kalafsky
-
Patent number: 5925668Abstract: The present invention provides compounds with antioxidant activity effective in treating free radical mediated diseases.Type: GrantFiled: January 20, 1998Date of Patent: July 20, 1999Assignee: ASTA Medica AktiengesellschaftInventors: Gerreke Biewenga, Guido R. M. M. Haenen, Aalt Bast
-
Patent number: 5922766Abstract: This invention relates to a palatable elemental nutritional formula that is nutritionally complete for humans with specialized dietary needs. The nutritional of the present invention uses specific free amino acids to provide the source of amino nitrogen (protein equivalents) and a special blend of fats that provides 38 to 50% of the total Calories in a pleasant tasting formula. The nutritionally complete formula of this invention is useful for children having multiple protein allergies, short gut syndrome, sick gut, diarrhea and the like. More specifically, the nutritional product, in accordance with this invention, utilizes L-asparagine monohydrochloride and L-glutamine in place of L-aspartic acid and L-glutamic acid, respectively. In addition, the source of fat comprises soy, fractionated coconut oil (medium chain triglycerides), high oleic safflower oil and esterified glycerol emulsifiers.Type: GrantFiled: July 2, 1997Date of Patent: July 13, 1999Inventors: Phyllis J. B. Acosta, Marlene W. Borschel, Patricia A. Reynolds, Christopher T. Cordle, Geralyn O. Duska-McEwen
-
Patent number: 5919816Abstract: This invention provides for pharmaceutical formulations of compounds which are useful as protective agents when administered to patients also receiving antineoplastic drugs. The invention also includes methods of reducing the toxicity of various antineoplastic agents by administering an effective amount of the protective agent to a patient receiving one or more antineoplastic agents. The compounds useful as protective agents have either a sulfhydryl moiety or are reducible disulfides.Type: GrantFiled: October 17, 1997Date of Patent: July 6, 1999Assignee: BioNumerik Pharmaceuticals, Inc.Inventors: Frederick H. Hausheer, Thomas J. Dodd
-
Patent number: 5889048Abstract: A pharmaceutical formulation having immunomodulating and regenerating effect on abnormal function of cell tissue division-regulating system comprises, as an active ingredient, mercury dichloride or potassium arsenite or sodium arsenate in the amount of 0.01-1.5% by weight and of a diluent up to 100% by weight. The proposed pharmaceutical formulation preferably contains natural white grape wine with sugar content of 3-4% by weight or whey with sugar content of 3-4% by weight as the diluent.Type: GrantFiled: August 19, 1996Date of Patent: March 30, 1999Inventor: Tamara Vasilievna Vorobieva
-
Patent number: 5880098Abstract: The present invention is directed to a therapy involving administering effective amounts of an organic osmolyte selected from the group consisting of polyols, amino acids and methyl amines, that regulate hydration of certain cells, for treating or preventing complications resulting from ischemia, hypoxia or oxidative stress.Type: GrantFiled: June 19, 1997Date of Patent: March 9, 1999Assignee: Pharmacia & Upjohn AktiebolagInventor: Dieter Haussinger
-
Patent number: 5874474Abstract: This invention is a composition and a method for treating animal skin ailments by a topical application of the composition to the animal in which the composition is a liquid or gel having potassium formate, sodium formate, or cesium formate in water in an effective concentration. Typically, the skin ailments treated are those caused by pyotraumatic dermatitis, chronic itching, scratching and chewing, and flea and insect bites in dogs, cats, horses and other animals.Type: GrantFiled: July 17, 1997Date of Patent: February 23, 1999Inventors: Thomas E. Peterson, Byron A. Church
-
Patent number: 5863563Abstract: Methods and compositions for the treatment of the symptoms of a patient who has a pulmonary condition associated with an inhibition of surfactant secretion by type II alveolar cells are described. The method of treatment involves causing a patient to inhale an amount of a pH-raising buffer effective to raise the pH of the aqueous fluid in the microenvironment of the type II alveolar cell lumenal surface, thereby inducing an increase in the rate of surfactant secretion by type II alveolar cells.Type: GrantFiled: October 20, 1994Date of Patent: January 26, 1999Assignee: AlphaGene Inc.Inventor: George Scheele
-
Patent number: 5830508Abstract: A calcium-based ophthalmic composition for treating dry eye is disclosed. The composition includes a hydrophobic carrier such as petrolatum and a calcium salt. The composition can further include a polyol such as glycerol, and an agent such as anhydrous lanolin, to enhance the interface between the carrier, and the calcium salt and polyol. Also disclosed is a method for treating dry eye comprising the step of administering the composition according to the present invention by placing the composition on the lateral portion of the lower eyelid margin. This method allows the composition to gradually disperse onto the cornea and conjunctiva.Type: GrantFiled: January 21, 1997Date of Patent: November 3, 1998Assignee: Deo CorporationInventor: Donald L. MacKeen
-
Patent number: 5786380Abstract: The invention provides compounds which are effective antiepileptics and at the same time display only a slight sedative and teratogenic effect and have the formula ##STR1## where the compounds of the formulae (I) and (II) can also be mono- or polyunsaturated, in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are each, independently of one another, hydrogen or a C.sub.1 -C.sub.6 -alkyl group, R.sup.5 is hydrogen or a C.sub.1 -C.sub.2 -alkyl group, and at least one of the radicals R.sup.1 to R.sup.4 in the compounds of the formulae (I) and (II) is different from hydrogen, where the compounds of the formula (I), in the case where a center of asymmetry is present on the carbon atom in position 2, and the compounds of the formulae (II), (III) and (IV) are in the form of their racemate, their pure enantiomers or a mixture of their enantiomers which differs from the racemate, and pharmaceutically compatible salts thereof.Type: GrantFiled: November 23, 1994Date of Patent: July 28, 1998Inventors: Heinz Nau, Ursula Bojic, Ralf-Siegbert Hauck, Mohamed Mohey Eldin Elmazar
-
Patent number: 5753706Abstract: Methods of controlling phosphate metabolism and metabolic acidosis in patients suffering from renal failure and associated hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition are provided. The method in accordance with this invention comprises administering to a patient a ferric-containing compound selected from the group consisting of ferric citrate, ferric acetate, and combinations thereof. Therapeutic benefit can be realized in accordance with such method by administering the compound orally to a patient to contact and bind with ingested phosphate in the patient's digestive tract, and thereby prevent its intestinal absorption.Type: GrantFiled: February 3, 1997Date of Patent: May 19, 1998Inventor: Chen Hsing Hsu
-
Patent number: 5733539Abstract: The invention discloses a bait for fishes and shellfishes characterized in that the bait comprises a matrix material containing a microorganically fermented product of a plant residue obtained by separating from a plant at least one liquid selected from the group consisting of vegetable juice, fruit juice, plant essential oil, juice extracted from a processed plant product, plant milk and mixtures thereof, or disintegrated product of said microorganically fermented product, wherein the matrix material has incorporated therein (A) an amino acid having 2 or 3 carbon atoms, and (B) amino acid having at least 4 carbon atoms in an (A)/(B) molar ratio of 1:1 to 40:1.Type: GrantFiled: July 13, 1997Date of Patent: March 31, 1998Assignee: Research Institute for Production DevelopmentInventors: Hisao Kitano, Masahiro Matsuda, Yasushi Ifuku, Hisao Maeda, Yoshifumi Matsuda
-
Patent number: 5726146Abstract: Dietary supplement formulation which increases lean body mass without concomitant increase of body fat mass, an effect parallel to that seen with usage of synthetic anabolic steroidal compounds but without adverse side-effects. The formulation composition of the invention comprises creatine, taurine, ribonucleic acid, and optimally, a carbohydrate (starch or a simple saccharide)component for enhancing cellular uptake. Other components such as alpha-ketoglutaric acid and salts thereof, and beta-hydroxy-beta-methyl butyric acid and salts thereof can be added for optimal results. The composition may be taken alone or in combination with a nutrient base, which typically includes protein source(s), carbohydrate(s), vitamin(s), and mineral(s) and other amino acids such as L-Glutamine and other natural L-form non-branched chain or branched chain amino acids. Actual studies in weight trained men show statistically significant increases in lean body mass yet with decreases in fat mass within 28 days.Type: GrantFiled: December 6, 1994Date of Patent: March 10, 1998Assignee: Natural Supplement Association, IncorporatedInventors: Anthony L. Almada, Edward A. Byrd
-
Patent number: 5719119Abstract: Parenteral nutrition aqueous solutions are provided which preferably contain glutamine together with other organic nitrogen containing compounds. The respective concentrations of the compounds present in any given such solution are typically approximately multiples of the concentration of the same compounds as found in normal human plasma, and the respective mole ratios of various such compounds in any given such solution relative to one another are approximately the same mole ratio associated with the same compounds as found in normal human plasma. Processes for using such solutions are provided.Type: GrantFiled: April 26, 1993Date of Patent: February 17, 1998Assignee: British Technology Group, Ltd.Inventor: Richard L. Veech
-
Patent number: 5714517Abstract: Fluorinated alkene compounds useful for and methods of controlling nematodes, insects, and acarids that prey on agricultural crops. Polar compounds, for example, 3,4,4-trifluoro-3-butene-1-amine or 3,4,4-trifluoro-3-butenoic acid, are particularly useful for systemic control of pests. Novel method and intermediates for the preparation of 3,4,4-trifluoro-3-butene-1-amine are also provided.Type: GrantFiled: August 22, 1996Date of Patent: February 3, 1998Assignee: Monsanto CompanyInventor: Peter Gerrard Ruminski
-
Patent number: 5670514Abstract: The present invention provides methods of inhibiting bone loss in mammals via the administration to a mammal in need of such treatment an effective amount of a compound from a series of benzoquinolin-3-ones. Such compounds also are sequentially or concurrently coadministered with a bone antiresorptive agent or a bone anabolic agent.Type: GrantFiled: March 28, 1996Date of Patent: September 23, 1997Assignee: Eli Lilly and CompanyInventors: James E. Audia, Blake L. Neubauer
-
Patent number: 5661123Abstract: The present invention provides a method for providing nutrition to non-catabolic and moderately catabolic patients. Pursuant to the present invention, the enteral composition includes a peptide based protein source of hydrolyzed whey, a lipid source, and a carbohydrate source. Preferably, the protein source includes approximately 22% to about 27% of the total calories. The composition has a caloric density of approximately 1000 Kcal/L and a low osmolality of approximately 300 to 450 mOsm/Kg H.sub.2 O. Still further, the composition of the present invention also includes increased levels of certain vitamins and minerals.Type: GrantFiled: January 17, 1995Date of Patent: August 26, 1997Assignee: Nestec, Ltd.Inventors: Lance Stalker, Diana Twyman, Shen-Youn Chang, Veronique Jaussan
-
Patent number: 5641790Abstract: A method of inhibiting bone loss or resorption, or lowering serum cholesterol, comprising administering to a human in need thereof a compound having the formula ##STR1## or a pharmaceutically acceptable salt or solvate thereof, in a low dosage amount. Also encompased by the invention is a a pharmaceutical formulation in unit dosage form comprising, per unit dosage, a low dosage amount.Type: GrantFiled: April 14, 1995Date of Patent: June 24, 1997Assignee: Eli Lilly and CompanyInventor: Michael W. Draper
-
Patent number: 5637305Abstract: L-carnitine acid azelate and its use for producing cosmetic and pharmaceutical compositions suitable to be topically applied for the treatment of dermatoses, are disclosed.Type: GrantFiled: June 7, 1995Date of Patent: June 10, 1997Assignee: Avantgarde S.p.A.Inventors: Claudio Cavazza, Paolo Cavazza
-
Patent number: 5610168Abstract: A method of inhibiting bone loss or resorption, or lowering serum cholesterol, comprising administering to a human in need thereof a compound having the formula ##STR1## or a pharmaceutically acceptable salt or solvate thereof, in a low dosage amount. Also encompased by the invention is a pharmaceutical formulation in unit dosage form comprising, per unit dosage, a low dosage amount.Type: GrantFiled: April 14, 1995Date of Patent: March 11, 1997Assignee: Eli Lilly and CompanyInventor: Michael W. Draper
-
Patent number: 5602180Abstract: A method of administering EDTA complexes includes steps of forming a suppository containing an EDTA complex and controlled-release agents which release the EDTA complex over a period of about three to four hours after placement, and then administering the suppository to a patient in lieu of an intravenous drip.Type: GrantFiled: March 31, 1995Date of Patent: February 11, 1997Assignee: World Health GroupInventor: Ronald Bennett
-
Patent number: 5589504Abstract: Based on the discovery that the human bilirubin/phenol UDP-glucuronosyltransferase ugt1 gene complex contains an electrophile responsive element and the knowledge that the rat NADP(H):quinone reductase gene contains an electrophile responsive element, agents which at a concentration of less than 50 .mu.M double the quinone reductase specific activity of Hepa 1clc7 cells, e.g., BHT and sulforaphane, are used for the prophylaxis or treatment of newborn jaundice.Type: GrantFiled: July 26, 1994Date of Patent: December 31, 1996Assignees: Cornell Research Foundation, Inc., Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva UniversityInventors: Andrew J. Dannenberg, Jayanta R. Chowdhury
-
Patent number: 5583089Abstract: This invention provides a dry blend pesticide composition which contains a fungicidal bicarbonate salt ingredient, and a spreader-sticker ingredient which is a crystalline clathrate complex of a urea constituent and a normally liquid spreader sticker constituent such as a nonionic surfactant. In a preferred embodiment all of the composition ingredients are water-soluble, and the composition is readily dispersible in an aqueous medium to form a sprayable pesticide solution.Type: GrantFiled: May 9, 1995Date of Patent: December 10, 1996Assignee: Church & Dwight Co., Inc.Inventor: Anthony E. Winston
-
Patent number: 5576337Abstract: A method of inhibiting the physiological disorder anxiety associated with an excess of neuropeptide Y or its symptoms comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.Type: GrantFiled: August 21, 1995Date of Patent: November 19, 1996Assignee: Eli Lilly and CompanyInventors: Robert F. Bruns, Jr., Donald R. Gehlert, J. Jeffry Howbert, William H. W. Lunn
-
Patent number: 5571808Abstract: A method for treating smoking-related bone loss comprising administering to a human in need thereof a pharmaceutically-effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, C.sub.1 -C.sub.4 alkyl, --CO--(C.sub.1 -C.sub.6 alkyl), or --CH.sub.2 Ar, --CO--Ar, wherein Ar is phenyl or substituted phenyl;R.sup.2 is selected from the group consisting of pyrrolidine, hexamethylenemino, and piperidino; or a pharmaceutically-acceptable salt thereof.Type: GrantFiled: January 31, 1995Date of Patent: November 5, 1996Assignee: Eli Lilly and CompanyInventor: James P. Leeds
-
Patent number: 5567714Abstract: A method of inhibiting obesity, a physiological disorder associated with an excess of neuropeptide Y, or its symptoms comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.Type: GrantFiled: August 21, 1995Date of Patent: October 22, 1996Assignee: Eli Lilly and CompanyInventors: Robert F. Bruns, Jr., Donald R. Gehlert, J. Jeffry Howbert, William H. W. Lunn
-
Patent number: 5567715Abstract: A method of inhibiting a physiological disorder associated with an excess of neuropeptide Y or its symptoms comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.Type: GrantFiled: August 21, 1995Date of Patent: October 22, 1996Assignee: Eli Lilly and CompanyInventors: Robert F. Bruns, Jr., Donald R. Gehlert, J. Jeffry Howbert, William H. W. Lunn
-
Patent number: 5550146Abstract: The present invention relates generally to a generic powder base rich in fats, carbohydrates, vitamins and minerals and trace elements which can be readily admixed with specific amino acids to yield several different therapeutic products for use in the nutritional support of various inherited metabolic diseases.Type: GrantFiled: April 18, 1995Date of Patent: August 27, 1996Assignee: Abbott LaboratoriesInventors: Phyllis J. B. Acosta, Richard A. Grondalski, Jeffrey W. Liebrecht, Patricia A. Reynolds
-
Patent number: 5547946Abstract: A method and topical pharmaceutical composition for treating respiratory allergies, allergic rhinitis, allergic conjunctivitis, allergic asthma, and allergy to fur and dust, in which free ion calcium plays a role in a subject. The composition is in the form of oral local and/or nasal liquid solution or suspension for instillation, inhalation or insufflation and includes as active agent, at least one compound selected from the group consisting of: DL-.alpha.-glycerophosphoric acid, glutaric acid and their sodium or potassium salts as the essential active agent. The active agent, when supplied in a sufficient amount, being effective to enable by a reduction in free ion calcium concentration the removal or improvement in symptoms of allergy amenable to said free calcium ion concentration reduction.Type: GrantFiled: November 15, 1993Date of Patent: August 20, 1996Assignee: Farmin S.r.l.Inventor: Giuliano Molinari
-
Patent number: 5534527Abstract: The current invention provides methods and pharmaceutical formulations that are useful for inhibiting the loss of bone. These methods and formulations can be used without the associated adverse effects of estrogen therapy, and thus serve as an effective and acceptable treatment for osteoporosis.Type: GrantFiled: April 14, 1995Date of Patent: July 9, 1996Assignee: Eli Lilly and CompanyInventors: Larry J. Black, George J. Cullinan
-
Patent number: 5525354Abstract: In a pharmaceutical preparation for oral use containing a pharmacologically acceptable salt of a bisphosphonic acid, the improvement comprising: a drug delivery form of the preparation which is enteric coated with a film which dissolves at a pH-value of from 5 to 7.2.Type: GrantFiled: December 12, 1994Date of Patent: June 11, 1996Assignee: Leiras OYInventors: Juhani Posti, Kirsi Katila, Pertti Rantala